Education
About Us
Working with TipRanks
Follow Us
Perseus Proteomics, Inc. (JP:4882)
:4882
4882 Stock Chart & Stats
¥220.00
-¥14.00(-2.34%)
At close: 4:00 PM EST
¥220.00
-¥14.00(-2.34%)
Day’s Range― - ―
52-Week Range¥203.00 - ¥1,113.00
Previous CloseN/A
Volume686.20K
Average Volume (3M)226.58K
Market Cap
¥3.24B
Enterprise Value¥4.42B
Total Cash (Recent Filing)¥1.51B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Feb 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.78
Shares Outstanding14,749,500
10 Day Avg. Volume184,610
30 Day Avg. Volume226,583
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.33
Price to Sales (P/S)87.24
P/FCF Ratio-13.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Perseus Proteomics, Inc. News
4882 FAQ
What was Perseus Proteomics, Inc.’s price range in the past 12 months?
Perseus Proteomics, Inc. lowest stock price was ¥203.00 and its highest was ¥1113.00 in the past 12 months.
What is Perseus Proteomics, Inc.’s market cap?
Perseus Proteomics, Inc.’s market cap is ¥3.24B.
When is Perseus Proteomics, Inc.’s upcoming earnings report date?
Perseus Proteomics, Inc.’s upcoming earnings report date is Feb 16, 2026 which is in 49 days.
How were Perseus Proteomics, Inc.’s earnings last quarter?
Perseus Proteomics, Inc. released its earnings results on Nov 14, 2025. The company reported -¥13.78 earnings per share for the quarter, missing the consensus estimate of N/A by -¥13.78.
Is Perseus Proteomics, Inc. overvalued?
According to Wall Street analysts Perseus Proteomics, Inc.’s price is currently Overvalued.
Does Perseus Proteomics, Inc. pay dividends?
Perseus Proteomics, Inc. does not currently pay dividends.
What is Perseus Proteomics, Inc.’s EPS estimate?
Perseus Proteomics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Perseus Proteomics, Inc. have?
Perseus Proteomics, Inc. has 14,749,500 shares outstanding.
What happened to Perseus Proteomics, Inc.’s price movement after its last earnings report?
Perseus Proteomics, Inc. reported an EPS of -¥13.78 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.572%.
Which hedge fund is a major shareholder of Perseus Proteomics, Inc.?
Currently, no hedge funds are holding shares in JP:4882
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Perseus Proteomics, Inc.
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Oncolys BioPharma, Inc.
―
FunPep Company Limited
―
Modalis Therapeutics Corporation
―
Kringle Pharma, Inc.
―
Cyfuse Biomedical K.K.
―